Role of IFNL4 Genotype in Hepatic Inflammation and Fibrosis due to Metabolic Dysfunction-Associated Steatotic Liver Disease
This study of over 4,000 individuals with metabolic dysfunction-associated steatotic liver disease (MASLD) found no evidence that the IFNL4-ΔG allele, which generates the IFN-λ4 protein, is associated with decreased hepatic inflammation or fibrosis, contrasting with previous findings in hepatitis C virus patients.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
The liver is the body's tireless chemical plant, filtering blood, storing energy, and neutralizing toxins. When this organ becomes clogged with excess fat, a condition now known as metabolic dysfunction-associated steatotic liver disease, it can trigger a slow, silent fire. This inflammation can scar the tissue, leading to fibrosis, a hardening that eventually compromises the organ's ability to function. For decades, scientists have searched for the genetic switches that determine why some people with fatty livers develop severe scarring while others do not. One such switch, located in a gene called interferon lambda 4, has been a prime suspect. In patients infected with the hepatitis C virus, specific versions of this gene were known to influence how well the body fought the infection and how much damage the virus caused. Because the gene is involved in the body's immune response, researchers wondered if it played a similar role in fatty liver disease, potentially acting as a shield against severe inflammation and scarring.
A large team of researchers set out to settle this question by examining the genetic makeup of more than 4,000 individuals across three distinct groups. They looked at adults with fatty liver disease who were part of a major national research network, a separate group of adults living with HIV who also had fatty liver disease, and a cohort of children with the condition. The scientists focused on a specific genetic variant that determines whether the body produces a protein called interferon lambda 4. In previous studies involving hepatitis C, the version of the gene that produces this protein was linked to better outcomes. However, when the researchers applied this same logic to fatty liver disease, the story changed completely. They found no evidence that carrying the gene variant that produces the protein offered any protection against liver inflammation or scarring in people with metabolic dysfunction-associated steatotic liver disease.
The study relied on a mix of direct and indirect measurements to assess liver health. For the largest group, consisting of over 2,000 adults and nearly 900 children, the researchers had access to actual tissue samples taken from liver biopsies. These samples allowed them to count the exact number of fat droplets, measure the level of inflammation, and grade the severity of scarring on a scale from none to cirrhosis. In the other two groups, where biopsies were not performed, the team used specialized ultrasound devices to estimate liver fat and stiffness, which serves as a proxy for scarring. Across all these groups, the genetic variant that generates the interferon lambda 4 protein showed no connection to the severity of the disease. Whether the participants were adults or children, or whether they were of different ethnic backgrounds, the presence of this gene did not predict who would have a more inflamed or scarred liver.
The findings held true even when the researchers looked specifically at people who were not obese, a subgroup where some earlier studies had suggested a link might exist. In the main group of adults with biopsy-proven disease, the genetic variant was not associated with higher or lower scores for fibrosis, inflammation, or overall disease activity. The results were consistent for children as well. In the group of adults living with HIV, the researchers did observe a connection, but it pointed in the opposite direction of what was expected. In non-Hispanic white adults with HIV, the gene variant was actually associated with higher liver stiffness, suggesting more scarring, rather than less. This result was not seen in the Black participants with HIV, and it contradicts the idea that this gene acts as a protective factor in fatty liver disease.
The researchers also took the time to re-examine data from three previous studies that had claimed to find a protective link between this gene and liver health. By using the same statistical methods and focusing on similar groups of people, they attempted to replicate those earlier positive findings. They could not. The large size of their new study gave them the statistical power to detect an effect if one existed, yet the signal remained absent. The authors concluded that the earlier reports of a protective effect were likely due to chance or differences in the specific populations studied. While the gene plays a well-documented role in fighting viral hepatitis, this comprehensive investigation provides no evidence that it influences the severity of inflammation or scarring caused by metabolic dysfunction-associated steatotic liver disease in the general population. The search for the genetic drivers of this common liver condition continues, but this particular candidate appears to be a bystander rather than a key player in the disease process.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.